# Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of Tolvaptan in Pediatric Congestive Heart Failure (CHF) Patients With Volume Overload

> **NCT03255226** · PHASE3 · COMPLETED · sponsor: **Otsuka Pharmaceutical Co., Ltd.** · enrollment: 60 (actual)

## Conditions studied

- Pediatric Congestive Heart Failure (CHF) Patients With Volume Overload

## Interventions

- **DRUG:** Tolvaptan

## Key facts

- **NCT ID:** NCT03255226
- **Lead sponsor:** Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-07
- **Primary completion:** 2021-07-11
- **Final completion:** 2021-07-15
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2024-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03255226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03255226, "Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of Tolvaptan in Pediatric Congestive Heart Failure (CHF) Patients With Volume Overload". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03255226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*